| Authors: |
Gillmore JD; University College London, National Amyloidosis Centre, Royal Free Hospital, London., Gane E; University of Auckland, Auckland, New Zealand., Täubel J; Richmond Pharmacology, London., Pilebro B; Umeå University, Umeå, Sweden., Echaniz-Laguna A; Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin-Bicêtre, France., Kao J; Auckland City Hospital, Auckland, New Zealand., Litchy W; Mayo Clinic, Rochester, MN., Shahda S; Intellia Therapeutics, Cambridge, MA., Haagensen A; Intellia Therapeutics, Cambridge, MA., Walsh L; Intellia Therapeutics, Cambridge, MA., Smith D; Intellia Therapeutics, Cambridge, MA., Kachadourian J; Intellia Therapeutics, Cambridge, MA., Ward JH; Intellia Therapeutics, Cambridge, MA., Lebwohl D; Intellia Therapeutics, Cambridge, MA., Zhu P; Intellia Therapeutics, Cambridge, MA., Xu Y; Intellia Therapeutics, Cambridge, MA., Leung A; Intellia Therapeutics, Cambridge, MA., Sonderfan A; Intellia Therapeutics, Cambridge, MA., Gutstein DE; Regeneron Pharmaceuticals, Tarrytown, NY., Manvelian G; Regeneron Pharmaceuticals, Tarrytown, NY., Adams D; Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Le Kremlin-Bicêtre, France. |
